Edwards Lifesciences Corporation research snapshot
EW AI stock analysis currently reads Edwards Lifesciences as a focused structural heart company with leading TAVR scale, fast-scaling TMTT adoption, and raised FY2026 sales growth guidance of 10% to 11% on a constant currency basis after a stronger than expected Q2 2026. At the August 2, 2026 data cutoff, EW closed at $86.07 on July 31, 2026, implying about $49.56 billion of verified market value, roughly 49x trailing EPS and about 28x forward earnings on the reaffirmed $2.95 to $3.05 adjusted EPS guidance. This EW AI stock forecast uses scenarios, not a certain price prediction, and is for informational use only.
Current price
$86.07
Market cap
$49.56 billion verified market cap
AI score
74 / 100
Rating
High-quality structural heart leader with raised guidance and a more reasonable valuation after the July pullback
Trend status
Corrective within a longer uptrend, above the 200-day moving average but below the 50-day moving average with RSI back near neutral
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Edwards sells structural heart devices used in high-acuity procedures, led by SAPIEN TAVR, TMTT repair and replacement therapies, and surgical structural heart products. | High |
| Moat | The moat comes from clinical evidence, physician familiarity, product training, manufacturing know-how, regulatory approvals, hospital workflow integration, and a large installed base in TAVR. | High |
| Management | CEO Bernard Zovighian is focusing Edwards on structural heart after the Critical Care divestiture, raising guidance after a stronger than expected Q2 2026 and reinvesting into R&D and buybacks. | Medium-high |
| Financial trend | Q2 2026 sales rose 13.6% to $1.741 billion with adjusted EPS of $0.78, TAVR grew 11.3%, and TMTT grew 47.3%. Edwards raised full year sales growth guidance to 10% to 11% constant currency. | High |
| Valuation | At $86.07, EW screens near 49.5x trailing EPS, 4.8x book value, 7.6x sales, 45.5x FCF, and 0% dividend yield based on audited tool math, with forward earnings near 27x to 29x. | High |
| Technical trend | Price sits between the moving averages after the July pullback. StockAnalysis listed the 50-day MA near $87.59, 200-day MA near $83.68, and RSI near 47.21, so momentum has cooled from overbought to neutral. | Medium |
| Risk level | Key risks include TAVR competition, the CMS NCD decision expected in September, reimbursement changes, slower procedure growth, durability questions in younger patients, product liability, clinical trial setbacks, foreign exchange, and tax changes. | Medium-high |
| AI confidence | High for current facts and calculations, medium for return ranges and chart timing. | High data confidence |
| Investment certainty | Medium. The business is better than average, the valuation is less demanding than in early July, but the stock still needs execution in TAVR, TMTT, Surgical, margins, and reimbursement. | Medium |
EW AI stock forecast
The EW AI stock forecast is scenario-based because Edwards value depends on TAVR growth, TMTT adoption, reimbursement and the CMS NCD, clinical evidence, gross margin, R&D productivity, competition, and the market multiple assigned to medtech growth. Using the $86.07 price reference, FY2026 adjusted EPS guidance midpoint near $3.00, and the audited three-scenario model, the mechanical three-year framework points to about $81.00 in a bear case, $119.80 in a base case, and $151.10 in a bullish case before any buyback effect beyond the model assumptions.
$145 to $155 before buyback effect
More likely if adjusted EPS compounds near 14%, TAVR grows near the high end of guidance, TMTT scales faster than expected, the CMS NCD expands Medicare access, gross margin holds near guidance, and investors keep EW near a mid-30s earnings multiple.
$115 to $125 before buyback effect
More likely if sales grow around 10% to 11%, adjusted EPS compounds near 10%, TAVR remains stable, TMTT keeps gaining adoption, and EW trades around 30x forward earnings.
$76 to $86 before buyback effect
More likely if procedure growth slows, competitors take share, the CMS NCD outcome disappoints, durability debate limits expansion, margin expansion stalls, or the market rerates high-multiple medtech stocks toward the low-20s earnings range.
EW AI technical analysis
EW AI technical analysis is corrective within a longer uptrend as of the August 2, 2026 data cutoff. StockAnalysis showed a July 31, 2026 close of $86.07, a 50-day moving average near $87.59, a 200-day moving average near $83.68, RSI near 47.21, and 20-day average volume near 5.21 million shares. The stock pulled back from roughly $94.82 in early July, and the setup favors waiting for a reclaim of the 50-day average or a defended 200-day average rather than aggressive position taking.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $86.07 | StockAnalysis listed the July 31, 2026 close at $86.07, down 0.98% on the day. |
| Near resistance | $87.60 to $88.50 | This is the 50-day moving-average area at $87.59, now acting as the first resistance after the pullback. |
| Upper resistance | $90 to $92 | This area is the early July congestion zone where EW traded before the decline from around $94.82. |
| 200-day moving average | $83.68 | StockAnalysis placed the 200-day moving average near $83.68, and the price is holding just above it. |
| Support zone | $80 to $83.68 | The round $80 level and the 200-day moving average form the main support zone below the current price. |
| Momentum | RSI near 47.21 | StockAnalysis showed RSI near neutral after cooling from the overbought zone, so the stock has room in both directions. |
| Volume | 20-day average near 5.21 million shares | A reclaim of the 50-day average is more credible if it happens on volume above the recent average. |
| Volatility | Moderate beta, high news sensitivity | StockAnalysis listed beta near 0.85, but the Q3 report, the September CMS NCD decision, and TCT data can still amplify moves. |
| Invalidation | Close below $83.68 | A sustained break below the 200-day moving average would weaken the current EW AI technical analysis setup and open the $80 area. |
EW AI trading strategy
The EW AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with TAVR growth, TMTT adoption, surgical structural heart demand, EPS guidance, margin targets, the CMS NCD review, clinical trial data, competition, and valuation discipline.
Watch for EW to reclaim the $87.60 to $88.50 area and then clear $90 to $92 on volume above recent averages, ideally with unchanged or higher FY2026 guidance and no negative update on the CMS NCD review or TAVR competitive position.
A failed reclaim followed by a close below the 200-day moving average near $83.68 should reduce trend confidence.
If EW holds the $83.68 support zone while guidance remains intact, compare the lower price with expected adjusted EPS growth, TMTT adoption, gross margin, R&D pipeline progress, buyback capacity, and the September CMS NCD decision.
Do not treat a pullback as automatically cheap. Recheck whether TAVR share, reimbursement, clinical evidence, or margin assumptions changed.
Track Q3 2026 sales and adjusted EPS against the $1.63 billion to $1.71 billion and $0.71 to $0.77 guidance, TAVR versus the 8% to 9% constant currency guide, TMTT versus the $760 million to $780 million guide, gross margin near the low end of 78% to 79%, operating margin near the high end of 28% to 29%, the September CMS NCD memo, and buyback pace.
Position sizing should reflect that EW is a high-quality medtech stock whose multiple still depends on reimbursement, clinical data, and market sentiment.
Investment research summary
Edwards is paid when hospitals and physicians use its structural heart devices to treat serious valve disease. Customers pay because TAVR, TMTT, and surgical valve products can address urgent clinical needs with proven device platforms and specialist support.
The moat is built on clinical data, physician trust, procedure training, regulatory approvals, manufacturing quality, product iteration, and a large TAVR installed base. It is not pure brand power because outcomes, reimbursement, and clinical evidence keep resetting the competitive test.
The thesis fails if TAVR growth slows, the CMS NCD outcome limits Medicare access, younger-patient durability concerns limit expansion, competitors gain share, TMTT adoption disappoints, or product liability and litigation costs rise.
Management should be judged by whether the post-Critical Care Edwards remains focused, funds R&D productively, defends TAVR leadership, scales TMTT, manages the California R&D credit tax impact, keeps margin discipline, and uses buybacks at prices that do not destroy per-share value.
Structural heart treatment is tied to aging populations, less invasive procedures, earlier diagnosis, clinical evidence, and hospital adoption. The trend is favorable, but procedure growth depends on referral patterns, reimbursement and CMS policy, capacity, and physician confidence.
At roughly 49x trailing EPS and about 28x forward earnings, EW is less expensive than in early July but still above the broad market. Margin of safety improves if the stock holds support while guidance and clinical momentum stay intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Share price | $86.07 close on July 31, 2026 | StockAnalysis EW financials | August 2, 2026 |
| Market capitalization | $49.56 billion, verified as $86.07 x 575.8 million shares | StockAnalysis EW statistics and financial_rigor.py | August 2, 2026 |
| Shares outstanding | 575.8 million shares | StockAnalysis EW statistics | August 2, 2026 |
| Q2 2026 sales | $1.741 billion, up 13.6% reported and 12.5% constant currency | Edwards Lifesciences Q2 2026 results | August 2, 2026 |
| Q2 2026 product-group sales | TAVR $1.258 billion up 11.3%, TMTT $195.9 million up 47.3%, Surgical $284.1 million up 6.5% | Edwards Lifesciences Q2 2026 results | August 2, 2026 |
| Q2 2026 adjusted EPS | $0.78 adjusted EPS; GAAP EPS of $0.42 | Edwards Lifesciences Q2 2026 results | August 2, 2026 |
| Raised FY2026 guidance | 10% to 11% constant currency sales growth, TAVR 8% to 9%, TMTT $760 million to $780 million, adjusted EPS $2.95 to $3.05 | Edwards Lifesciences Q2 2026 results | August 2, 2026 |
| Cash and short-term investments | $3.672 billion as of March 31, 2026; about $2.9 billion cash on June 30, 2026 | StockAnalysis EW balance sheet and Q2 2026 press release | August 2, 2026 |
| Total debt | $702.9 million as of March 31, 2026; about $600 million on June 30, 2026 | StockAnalysis EW balance sheet and Q2 2026 press release | August 2, 2026 |
| Technical trend | 50-day MA near $87.59, 200-day MA near $83.68, RSI near 47.21 | StockAnalysis EW statistics | August 2, 2026 |
| Analyst consensus | Consensus Buy, average price target $100.96, range $84 to $110 across 28 analysts | StockAnalysis EW forecast | August 2, 2026 |
| Risk factor categories | Innovation, clinical trials, manufacturing, competition, reimbursement and the CMS NCD, regulation, IP, product liability, cybersecurity, tax changes, and international risks | Edwards Lifesciences 2025 Form 10-K and Q2 2026 press release | August 2, 2026 |
This EW AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a personalized trading plan. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if earnings, clinical evidence, the CMS NCD outcome, competition, valuation multiples, tax changes, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
